Japan-based Fujikura Kasei will exercise its option to licence the midkine (MK) diagnostic technology and will make a JPY40 million ($403,000) payment as milestone fee to Australia-based Cellmid. The companies signed the option to license ...
Australian biotechnology company Cellmid has entered into an option agreement with Japanese company Fujikura Kasei. Under the option to license agreement, Cellmid will supply its proprietary anti-midkine diagnostic antibodies for ...
Tags: Cellmid, Fujikura Kasei, anti-midkine diagnostic antibodies